| Name | FAUC-365 |
| Description | FAUC-365 is a D3 dopamine receptor agonist. |
| In vitro | As a dichloro derivative, FAUC-365 revealed D3 affinities that were comparable to its methoxy-substituted analogs, however, the selectivities of FAUC-365 against 5HT-1A, 5-HT2, and R1 were substantially higher, which was demonstrated by the extraordinary selectivity ratios of 17600, 7200, 5200, and 680 over D1, D2long, D2short, and D4, respectively, were determined for FAUC-365 with Ki of 0.50 nM. In addition, the benzothiophene analog FAUC 346 and its oxa analog showed partial agonist character with EC50 values at 0.36 and 1.5 nM, respectively [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : insoluble DMSO : 50 mg/mL (108.12 mM), Sonication is recommended. EtOH : insoluble 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.32 mM), Sonication is recommended.
|
| Keywords | SPET | schizophrenia | Radioligand | Parkinson's disease | Inhibitor | inhibit | FAUC-365 | FAUC365 | FAUC 365 | DopamineReceptor | Dopamine Receptor | Dopamine | D3 receptor | D3 |
| Inhibitors Related | Trifluoperazine dihydrochloride | Clozapine N-Oxide | Mirtazapine | Hexamethonium Bromide | Butyrophenone | Octopamine hydrochloride | L-DOPA | Creatine | Dopamine hydrochloride | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |